Aprutumab, {a specific antibody-drug conjugate, represents {a significant advance in treating cancers characterized by FGFR2 mutations. This targeted therapy functions by specifically binding to FGFR2, a receptor often https://aprutumabhighpurity811511.activoblog.com/profile